Your browser doesn't support javascript.
loading
Chemical modification of the adeno-associated virus capsid to improve gene delivery.
Mével, Mathieu; Bouzelha, Mohammed; Leray, Aurélien; Pacouret, Simon; Guilbaud, Mickael; Penaud-Budloo, Magalie; Alvarez-Dorta, Dimitri; Dubreil, Laurence; Gouin, Sébastien G; Combal, Jean Philippe; Hommel, Mirja; Gonzalez-Aseguinolaza, Gloria; Blouin, Véronique; Moullier, Philippe; Adjali, Oumeya; Deniaud, David; Ayuso, Eduard.
Afiliación
  • Mével M; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr.
  • Bouzelha M; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr.
  • Leray A; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr.
  • Pacouret S; LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques 44322 Nantes France david.deniaud@univ-nantes.fr.
  • Guilbaud M; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr.
  • Penaud-Budloo M; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr.
  • Alvarez-Dorta D; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr.
  • Dubreil L; LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques 44322 Nantes France david.deniaud@univ-nantes.fr.
  • Gouin SG; PanTher-UMR 703, INRA-ONIRIS, Atlanpole-Chanterie 44307 Nantes France.
  • Combal JP; LUNAM Université, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR CNRS 6230, UFR des Sciences et des Techniques 44322 Nantes France david.deniaud@univ-nantes.fr.
  • Hommel M; Vivet Therapeutics SAS Paris France.
  • Gonzalez-Aseguinolaza G; Gene Therapy and Regulation of Gene Expression Program, CIMA, FIMA, University of Navarra, Navarra Institute for Health Research (IdisNA) Pamplona Spain.
  • Blouin V; Vivet Therapeutics SAS Paris France.
  • Moullier P; Gene Therapy and Regulation of Gene Expression Program, CIMA, FIMA, University of Navarra, Navarra Institute for Health Research (IdisNA) Pamplona Spain.
  • Adjali O; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr.
  • Deniaud D; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr.
  • Ayuso E; INSERM UMR 1089, Université de Nantes, CHU de Nantes 44200 Nantes France mathieu.mevel@univ-nantes.fr eduard.ayuso@univ-nantes.fr.
Chem Sci ; 11(4): 1122-1131, 2019 Dec 09.
Article en En | MEDLINE | ID: mdl-34084369
ABSTRACT
Gene delivery vectors based on adeno-associated virus (AAV) are highly promising due to several desirable features of this parent virus, including a lack of pathogenicity, efficient infection of dividing and non-dividing cells and sustained maintenance of the viral genome. However, the conclusion from clinical data using these vectors is that there is a need to develop new AAVs with a higher transduction efficiency and specificity for relevant target tissues. To overcome these limitations, we chemically modified the surface of the capsid of AAV vectors. These modifications were achieved by chemical coupling of a ligand by the formation of a thiourea functionality between the amino group of the capsid proteins and the reactive isothiocyanate motif incorporated into the ligand. This strategy does not require genetic engineering of the capsid sequence. The proof of concept was first evidenced using a fluorophore (FITC). Next, we coupled the N-acetylgalactosamine ligand onto the surface of the AAV capsid for asialoglycoprotein receptor-mediated hepatocyte-targeted delivery. Chemically-modified capsids also showed reduced interactions with neutralizing antibodies. Taken together, our findings reveal the possibility of creating a specific engineered platform for targeting AAVs via chemical coupling.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Chem Sci Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Chem Sci Año: 2019 Tipo del documento: Article
...